Mal-PEG2-Val-Cit-PABA-PNP (Synonyms: Mal-PEG2-Val-Cit-PABA-PNP; Mal-PEG2-Val-Cit-PABA-PNP)

Mal-PEG2-Val-Cit-PABA-PNP is a cleavable ADC linker containing two PEG units, which can be used in the synthesis of antibody-drug conjugates (ADCs) [1].

Mal-PEG2-Val-Cit-PABA-PNP (CAS:1345681-52-8) is a small molecule drug that contains several functional groups. The Mal group, which is a reactive functional group, can specifically react with thiol groups on proteins. This characteristic enables the drug to target specific proteins in the body. The PEG2 group is a polyethylene glycol spacer that can enhance the solubility and stability of the drug in solution. Val and Cit groups are amino acids that help form a peptide bond, which is an essential structural component of the drug. The PABA group can be used to link the drug to other molecules, and the PNP group serves as a leaving group in chemical reactions.

This combination of Mal-PEG2-Val-Cit-PABA-PNP functional groups is designed to create a drug that can target specific proteins or biological processes in the body. For instance, the Mal group can specifically target overexpressed proteins in certain types of cancer cells, leading to more effective treatment. The PEG2 spacer can improve the pharmacokinetic properties of the drug, while the amino acid groups contribute to the drug's stability. The PABA group can be used to link the drug to other molecules such as antibodies, creating a more precise and targeted therapy.

References:
[1]. Beck A, Goetsch L, Dumontet C, CorvaÏa N. Strategies and challenges for the next generation of antibody-drug conjugates. Nature reviews Drug discovery. 2017 May;16(5):315-37.